8-K current report · filed Nov 9, 2026

Immunome Inc. (IMNM) 8-K Current Report: November 9, 2026

Item 2.02Item EX-99.1IMNM overview

Short answer

Immunome Inc. (IMNM) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results for quarter ended September 30, 2026 announced.

Immunome Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 announced
  • Business update included alongside quarterly financial results
  • Investor-relevant figures and outlook available in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 net loss $85.8M, with operating expenses $90.4M versus $60.1M year over year
  • Cash, equivalents and marketable securities $461.6M, expected to fund operations into 2028
  • Varegacestat FDA decision targeted April 28, 2027, while EMA validated its marketing application
  • IM-1021 showed 53% objective response rate in B-NHL, including five complete responses among 19 evaluable patients
  • Pipeline expansion: IM-1340 IND cleared, Phase 1 expected by year-end 2026; updated IM-1021 data due December 14

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Immunome Inc. 8-K filings

Get the next IMNM 8-K as it lands

Follow IMNM for push alerts, or ask the research agent what this filing means.